How does WIPO Standard ST.26 relate to the MPEP’s definition of “modified amino acid”?
WIPO Standard ST.26 plays a crucial role in the MPEP’s definition of “modified amino acid”. According to MPEP 2412.03(c): “Modified amino acid” includes any amino acid as described in paragraph 3(e) of WIPO Standard ST.26. The MPEP directly incorporates the WIPO Standard ST.26 definition, making it an integral part of the USPTO’s guidelines for patent…
Read MoreHow does the MPEP define standard amino acids?
While the MPEP doesn’t directly define standard amino acids, it indirectly provides this information by referencing WIPO Standard ST.26. According to MPEP 2412.03(c): WIPO Standard ST.26, paragraph 3(e), identifies “modified amino acid” to mean any amino acid as described in the definition of “amino acid”, other than L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic…
Read MoreWhen did the new rules for “modified amino acids” in patent applications come into effect?
The new rules regarding “modified amino acids” in patent applications came into effect on July 1, 2022. This is clearly stated in the MPEP 2412.03(c): [Editor Note: This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]…
Read MoreWhat is considered a “modified amino acid” according to the MPEP?
According to MPEP 2412.03(c), a “modified amino acid” is defined as follows: “Modified amino acid” includes any amino acid as described in paragraph 3(e) of WIPO Standard ST.26. This definition is further elaborated in WIPO Standard ST.26, which states that a modified amino acid is any amino acid other than the 22 standard amino acids…
Read MoreWhat regulation governs the requirements for patent applications with nucleotide and/or amino acid sequence disclosures?
The requirements for patent applications with nucleotide and/or amino acid sequence disclosures are governed by 37 CFR 1.831. This is referenced in MPEP 2412.03(c): 37 CFR 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures. This regulation sets forth the specific requirements that patent applicants…
Read More